Sugi Predict

Sugi Predict / Compounds / SCHEMBL1473020

SCHEMBL1473020

SCHEMBL1473020

c1ccc(-c2noc(-c3ccccc3)n2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H4 Q96RI1 3/20 1.00
▸ SMN1; SMN2 Q16637 11/20 0.81
▸ RAB9A P51151 8/20 0.78
▸ NPC1 O15118 7/20 0.78
▸ NFKB1 P19838 5/20 0.78
▸ NFKB2 Q00653 5/20 0.78
▸ RELA Q04206 5/20 0.78
▸ MAPT P10636 6/20 0.75
▸ HSD17B10 Q99714 4/20 0.75
▸ GPR55 Q9Y2T6 1/20 0.70
▸ S1PR1 P21453 1/20 0.70
▸ TP53 P04637 6/20 0.69
▸ KDM4E B2RXH2 3/20 0.69
▸ MEN1 O00255 3/20 0.69
▸ ALDH1A1 P00352 3/20 0.69
▸ KMT2A Q03164 3/20 0.69
▸ MAPK1 P28482 3/20 0.69
▸ L3MBTL1 Q9Y468 3/20 0.69
▸ CYP1A2 P05177 1/20 0.69
▸ CA2 P00918 2/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL321073 0.96 NR1H4 (0.91) NR1H4SMN1; SMN2RAB9ANPC1NFKB1
SCHEMBL17640602 0.96 NR1H4 (0.91) NR1H4SMN1; SMN2RAB9ANPC1NFKB1
SCHEMBL12895776 0.91 NR1H4 (0.83) NR1H4SMN1; SMN2RAB9ANPC1NFKB1
SCHEMBL2810636 0.90 NR1H4 (1.00) NR1H4SMN1; SMN2RAB9ANPC1NFKB1
SCHEMBL3737008 0.90 SMN1; SMN2 (1.00) NR1H4SMN1; SMN2RAB9ANPC1NFKB1
SCHEMBL17570197 0.89 NR1H4 (0.80) NR1H4SMN1; SMN2RAB9ANPC1NFKB1
SCHEMBL13415309 0.89 NR1H4 (0.80) NR1H4SMN1; SMN2RAB9ANPC1NFKB1
SCHEMBL713159 0.88 NR1H4 (0.78) NR1H4SMN1; SMN2RAB9ANPC1NFKB1
SCHEMBL16592554 0.88 NR1H4 (0.78) NR1H4SMN1; SMN2RAB9ANPC1NFKB1
SCHEMBL3059321 0.88 NR1H4 (0.78) NR1H4SMN1; SMN2RAB9ANPC1NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4115976-B1 REACTION VESSEL ALOIS DATA GMBH (DE) 2026-04-29 — — EP disclosed
EP-4619148-A1 REACTION VESSEL WITH STATOR INSERT AND ROTOR Prosperodes GmbH (DE) 2025-09-24 — — EP disclosed
US-20250228242-A1 PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2025-07-17 — — US disclosed
CN-116217508-B Oxadiazole compound for protecting beta cells to treat type II diabetes, and preparation method and application thereof 浙江工业大学 2024-12-17 — — CN disclosed
US-20240329059-A1 REACTION VESSEL ALOIS DATA GMBH (DE) 2024-10-03 — — US disclosed
CN-118265453-A Protein aggregation inhibiting compounds for plant disease control 马克斯·普朗克科学促进学会 2024-06-28 — — CN disclosed
WO-2024132916-A1 REACTION VESSEL WITH STATOR INSERT AND ROTOR PROSPERODES GMBH (DE) 2024-06-27 — — WO disclosed
EP-4389272-A1 REACTION VESSEL WITH STATOR INSERT AND ROTOR Prosperodes GmbH (DE) 2024-06-26 — — EP disclosed
EP-4384013-A1 PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) 2024-06-19 — — EP disclosed
WO-2024064080-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2024-03-28 — — WO disclosed
WO-2009023854-A1 BICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2009-02-19 — — WO disclosed
US-20090042955-A1 BICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS UNIVERSITY OF VIRGINIA PATENT FOUNDATION 2009-02-12 — — US disclosed
US-20080280876-A1 Novel oxadiazole compounds ABBVIE INC. 2008-11-13 — — US disclosed
EP-1987013-A1 BICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2008-11-05 — — EP disclosed
WO-2008124210-A1 METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING INFECTION USING LEUKOCYTE SEQUESTRATION AGENTS EMORY UNIVERSITY (US) 2008-10-16 — — WO disclosed
WO-2008064337-A2 BENZOCYCLOHEPTYL ANALOGS HAVING SPHINGOSINE 1-PHOSPHATE RECEPTOR ACTIVITY UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2008-05-29 — — WO disclosed
WO-2008064320-A2 HYDRINDANE ANALOGS HAVING SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONIST ACTIVITY UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2008-05-29 — — WO disclosed
WO-2008064315-A1 TETRALIN ANALOGS HAVING SPHINGOSINE 1-PHOSPHATE AGONIST ACTIVITY UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2008-05-29 — — WO disclosed
WO-2007092638-A1 BICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2007-08-16 — — WO disclosed
US-6277872-B1 ANTIISCHEMIC AGENTS; BRAIN DISORDERS BOEHRINGER INGELHEIM KG (DE) 2001-08-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042955-A1 BICYCLIC SPHINGOSINE 1-PHOSPHATE ANALOGS S1PR1, S1PR4, S1PR3 NR1H4 459/4885SMN1; SMN2 1643/4885RAB9A 3172/4885
US-20250228242-A1 PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL APP, APBA1, PRNP NR1H4 4814/4885SMN1; SMN2 4191/4885RAB9A 1693/4885
US-20080280876-A1 Novel oxadiazole compounds S1PR3, S1PR1, S1PR2 NR1H4 390/4885SMN1; SMN2 3564/4885RAB9A 2582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.